ESMO: Amgen's Lumakras confirmatory lung cancer data are here, fanning KRAS battle flames

In a closely watched competition among KRAS inhibitors, Amgen leads the pack with a randomized trial win in lung cancer. Now, the California drugmaker is giving a first look at the detailed data that could set the bar for all others to come, including Mirati Therapeutics, Roche and Novartis.